Tag Archives: Zepatier

September, 2017

  • 29 September

    Merck Discontinues MK-3682B and MK-3682C Development Programs

    KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced its strategic decision to discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/ uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. This decision was made based on …

February, 2017

  • 22 February

    The 2017 Hepatitis C Treatment Landscape

    Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, particularly when it comes to direct-acting antiviral medications. This included various drug approvals and access improvements for hepatitis C medications, including Daklinza, Epclusa, Sovaldi/velpatasvir, Viekira, and Zepatier. As we make our way deeper into 2017, …

November, 2016

  • 22 November

    HCV Research Round-up

    Hepatitis C treatment options continue to be a vibrant field full of exciting research, including the following: Genotype 3 of the hepatitis C virus (HCV) has remained harder-to-treat among the six main genotypes. New research presented at the 2016 AASLD conference now offers promising news for treating genotype 3. According …

September, 2016

  • 27 September

    Breaking Down Restrictions

    For many years, the standard plan for treating hepatitis C infections called for excluding active drug users. Experts at the 5th International Symposium on Hepatitis Care in Substance Users who recently met in Oslo, aim to revise what is considered standard care. New research was discussed at the symposium, specifically …

February, 2016

  • 2 February

    Meet Zepatier

    There’s a new option in the treatment of hepatitis C, with the U.S. Food and Drug Administration (FDA) approving Merck’s Zepatier™ (elbasvir and grazoprevir) just a few days ago on January 28, 2015. This medication’s entry to the treatment field came on an accelerated track with the FDA granting it …